CAR T Cell Therapy for T Cell Leukemia and Lymphoma: Latest Updates From 2022 ASH Annual Meeting

Authors

Qiusha Huang, Peking University People's Hospital, Peking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, National Clinical Research Center for Hematologic Disease, Beijing, China.
Xiao-Hui Zhang, Peking University People's Hospital, Peking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, National Clinical Research Center for Hematologic Disease, Beijing, China. zhangxh@bjmu.edu.cn.
Delong Liu, New York Medical College and Westchester Medical Center, Valhalla, NY, 10595, USA.

Author Type(s)

Faculty

Journal Title

Journal of Hematology & Oncology

First Page

18

Document Type

Article

Publication Date

3-5-2023

Department

Medicine

Abstract

Due to the concern of fratricide, clinical development of CAR T cells for the therapy of T cell malignancies lags behind that for B cell malignancies. Attempts are being made to revise T cell biomarkers so that the re-engineered CAR T cells can target T cell malignancies. CD3 and CD7 are the two pan-T cell surface biomarkers that have been either knocked out or knocked down through genome base- editing technology or by protein expression blockers so that the re-engineered T cells can target T cells without fratricide. We summarized several latest reports on the CAR T cells for the therapy of T cell leukemia /lymphoma from the 2022 ASH Annual Meeting, with latest updates on clinical trials of TvT CAR7, RD-13-01, and CD7 CART.

Recommended Citation

Huang, Q., Zhang, X., & Liu, D. (2023). CAR T Cell Therapy for T Cell Leukemia and Lymphoma: Latest Updates From 2022 ASH Annual Meeting. Journal of Hematology & Oncology, 16 (1), 18. https://doi.org/10.1186/s13045-023-01406-8